If you haven't heard about takotsubo cardiomyopathy, also known as "broken heart syndrome," you may be surprised to find that one to two percent of people who are initially suspected of having a heart attack are finally discovered to have this increasingly recognized syndrome. New research suggests the condition that temporarily causes heart failure in people who experience severe stress might actually protect the heart from very high levels of adrenaline.
The study was published this week in the journal Circulation and provides the first physiological explanation for Takotsubo cardiomyopathy.
Patients with takotsubo cardiomyopathy, most often older women, experience symptoms that resemble a heart attack, but heart tests reveal no blockage in the coronary arteries. Instead the heart has a balloon-like appearance caused by the bottom of the heart not contracting properly.
The Imperial College London study, which simulated the condition in rats, suggests that the body changes its response to adrenaline under severe overload, switching from its usual role of stimulating the heart to reducing the heart's pumping power. Although this results in acute heart failure, most patients make a full recovery within days or weeks.
The researchers propose that the switch in the heart's response to adrenaline might have evolved to protect the heart from being overstimulated by the particularly high doses of adrenaline that the body releases during stress.
In this new research, the authors simulated the condition by injecting high doses of adrenaline into anesthetized rats. In these rats, as in Takotsubo patients, heart muscle contraction was suppressed towards the bottom of the heart.
The researchers found that these rats were protected from an otherwise fatal over-stimulation of the heart, indicating that adrenaline acts through a different pathway from usual, and that this switch protects the heart from toxic levels of adrenaline.
The study also examined drugs that might be useful for treating takotsubo cardiomyopathy. Some beta blockers, used to treat high blood pressure, angina and heart failure, reproduced or enhanced the features of Takotsubo, giving new insights into the protective effects of these drugs. Levosimendan, a different type of drug given in heart failure to stimulate the heart without going through the adrenaline receptor pathways, had a beneficial effect.
"Adrenaline's stimulatory effect on the heart is important for helping us get more oxygen around the body in stressful situations, but it can be damaging if it goes on for too long," said Professor Sian Harding, from the National Heart and Lung Institute (NHLI) at Imperial College London, who led the study. "In patients with Takotsubo cardiomyopathy, adrenaline works in a different way and shuts down the heart instead. This seems to protect the heart from being overstimulated."
Study co-author Dr. Alexander Lyon, also from the National Heart and Lung Institute (NHLI) at Imperial, and consultant cardiologist at Royal Brompton Hospital, set up one of the first specialist services in the UK to look after people who have experienced the condition.
"Currently it is not fully known how to treat these patients," he said. "Insights from this work show that the illness may be protecting them from more serious harm. We've identified a drug treatment that might be helpful, but the most important thing is to recognise the condition, and not to make it worse by giving patients with takotsubo cardiomyopathy more adrenaline or adrenaline-like medications."
"At the Royal Brompton Hospital and Imperial College London we are leading a European initiative to bring together experts to understand this recently recognised cardiac syndrome, and we hope the findings from this work will lead to new treatment strategies for these patients during the acute phase of their illness, and to prevent recurrence."
Dr Shannon Amoils, Research Advisor at the British Heart Foundation, who helped fund the research, said: "The study also provides new insights into how the heart may protect itself from stress, which opens up exciting avenues of exploration for research. We must remember though that this is a study in rats, and the findings need to be confirmed in people before we can be sure of their relevance to patients."
In addition to the British Heart Foundation, funding for the study came from the Wellcome Trust, the Biotechnology and Biological Sciences Research Council and the Academy of Medical Sciences.
Source: Imperial College London
See the stories that matter in your inbox every morning